Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Recommendation of "Hold" from Brokerages

Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has earned a consensus rating of "Hold" from the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $6.11.

A number of equities analysts have recently commented on the stock. Wedbush downgraded shares of Sutro Biopharma from an "outperform" rating to a "neutral" rating and reduced their price objective for the stock from $8.00 to $2.00 in a report on Friday, March 14th. Bank of America reduced their price objective on shares of Sutro Biopharma from $1.00 to $0.80 and set an "underperform" rating for the company in a report on Monday, May 19th. Piper Sandler raised shares of Sutro Biopharma from a "neutral" rating to an "overweight" rating and set a $2.00 price objective for the company in a report on Monday, June 16th. Citizens Jmp downgraded shares of Sutro Biopharma from an "outperform" rating to a "market perform" rating in a report on Friday, March 14th. Finally, HC Wainwright reaffirmed a "neutral" rating and set a $2.00 price objective on shares of Sutro Biopharma in a report on Tuesday, April 29th.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN raised its stake in shares of Sutro Biopharma by 24.8% in the fourth quarter. Wells Fargo & Company MN now owns 52,738 shares of the company's stock valued at $97,000 after acquiring an additional 10,466 shares during the last quarter. ProShare Advisors LLC raised its position in Sutro Biopharma by 74.3% in the 4th quarter. ProShare Advisors LLC now owns 26,961 shares of the company's stock worth $50,000 after purchasing an additional 11,494 shares during the last quarter. Parkman Healthcare Partners LLC raised its position in Sutro Biopharma by 0.7% in the 4th quarter. Parkman Healthcare Partners LLC now owns 1,727,925 shares of the company's stock worth $3,179,000 after purchasing an additional 11,793 shares during the last quarter. Invesco Ltd. raised its position in Sutro Biopharma by 54.2% in the 4th quarter. Invesco Ltd. now owns 38,749 shares of the company's stock worth $71,000 after purchasing an additional 13,620 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in Sutro Biopharma in the 4th quarter worth approximately $26,000. Institutional investors own 96.99% of the company's stock.

Sutro Biopharma Price Performance

NASDAQ STRO opened at $0.82 on Friday. The firm has a market capitalization of $69.07 million, a price-to-earnings ratio of -0.27 and a beta of 1.64. The company's fifty day moving average is $0.85 and its two-hundred day moving average is $1.20. Sutro Biopharma has a 52-week low of $0.52 and a 52-week high of $5.17.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.28). The company had revenue of $17.40 million during the quarter, compared to analyst estimates of $11.61 million. Sutro Biopharma had a negative return on equity of 347.60% and a negative net margin of 373.66%. As a group, sell-side analysts expect that Sutro Biopharma will post -2.92 earnings per share for the current fiscal year.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.